Thomas G.Rowan (Tom)

Of Counsel

New York + 1.212.326.3766

Tom Rowan has more than 25 years of experience representing clients in all areas of patent law. This includes patent enforcement strategies, patent procurement, patent portfolio management, opinions, due diligence, negotiations, and litigation.

His work has involved a broad range of technologies in areas including pharmaceuticals, biotechnology, chemical compounds and processes, medical and orthopedic devices, magnetic materials, vitamin supplements, and cosmetics. Among the clients for whom he has worked are Purdue Pharma, Indena, Arcade, Magnequench, Musculoskeletal Transplant Foundation, and Voyager Therapeutics.

Tom has represented clients in patent infringement actions before federal district courts throughout the United States, as well as appeals before the Court of Appeals for the Federal Circuit. He also has litigated cases before the International Trade Commission, including a case that led to a general exclusion order against a number of foreign respondents who were importing infringing magnetic materials into the United States. In addition, he has represented clients before the USPTO Patent Trial and Appeal Board.

Tom is a member of the New York Intellectual Property Law Association and the Federal Circuit Bar Association.

Experience

  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Molycorp forms joint venture with Mitsubishi and Daido Steel to manufacture rare earth magnetsJones Day advised Molycorp Minerals LLC with its entry into a Japanese joint venture with Mitsubishi Corporation and Daido Steel.
  • Cougar Biotechnology builds global patent portfolio for prostate cancer treatmentOn behalf of Cougar Biotechnology, Inc. Jones Day assisted with the development of its global patent portfolio related to the use of 17 alpha-hydroxylase/C17,20-lyase inhibitors to treat cancer.
  • Cougar Biotech gets purchased by J & J, including global patent portfolio for prostate cancer treatmentJones Day assisted Cougar Biotechnology in the management and prosecution of a worldwide patent portfolio for the phase III clinical candidate, abiraterone acetate, which is being developed for use in the treatment of prostate cancer and which resulted in the sale of Cougar to Johnson & Johnson for $970 million.
  • Musculoskeletal Transplant Foundation establishes global patent portfolio for bone implantsJones Day assisted Musculoskeletal Transplant Foundation ("MTF") in the development of its global patent portfolio relating to bone implants.
  • Musculoskeletal Transplant Foundation defends against patent infringement claims related to bone-cleaning and demineralization technologyJones Day represented the Musculoskeletal Transplant Foundation, Inc. (MTF), a non-profit tissue bank, in defending against claims of patent infringement brought by another non-profit tissue bank for technology relating to bone-cleaning and demineralization.
  • Magnequench faces interference dispute with Naval Research Lab before USPTOJones Day represented Magnequench in a patent interference against the Naval Research Laboratory involving a pioneering patent on rare earth-iron-boron magnetic material.
  • Osteologix develops global patent portfolio for technology used in treating bone diseasesJones Day represented Osteologix, Inc. in the establishment of its global patent portfolio relating to the use of its clinical candidate strontium malonate, to treat bone diseases.
  • Purdue Pharma pursues patent infringement charges against generic-drug maker over oxycodone formulationsJones Day provided ongoing representation of various Purdue Pharma entities in a lawsuit against Teva Pharmaceuticals relating to Purdue's patent portfolio on controlled released oxycodone opiod formulations for the treatment of moderate to severe pain.
  • Magnequench pursues patent infringement claims against Sony involving magnetic compositions for optical disk drivesJones Day represented Magnequench International, Inc. in a patent infringement action against numerous retailers and manufacturers of optical disk drive products using advanced magnetic compositions.
  • Magnequench files patent infringement charges against Samsung involving magnetic compositions for optical disk drivesJones Day represented Magnequench International Inc. in an action involving patent infringement by Samsung products containing optical disk drives using advanced magnetic compositions.
  • Enzymatic Therapy pursues patent litigation relating to glucosamine sulfate compositionsJones Day represented Enzymatic Therapy in a patent litigation involving glucosamine sulfate compositions.
  • ATOFINA establishes patent portfolio for polymers and related materials and processesOn behalf of ATOFINA Petrochemicals, Inc., Jones Day managed the patent portfolio and prosecuted key patents related to polymers and their preparation, polymer blends, plastics, rubber, engineered materials, and chemical processes.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.